Table 1.

Early and late mortality in the PARTNER trial

	High-risk operable patients			Inoperable patients
				Pivotal trial			Cont. access		Combined*
	TAVI	AVR	p Value	TAVI	Stand.	p Value	TAVI	Stand.	TAVI	Stand.
N	348	351		179	179		41	49	220	228
30-day mortality	3.4%	6.5%	0.07	5.0%†	2.8%	0.41	9.8%	2.1%	5.9%	2.7%
1-year mortality	24.2%	26.8%	0.44	30.7%	50.7%	<0.001	34.3%	21.6%	31.4%	43.7%

Sources: high-risk operable patients: Smith et al²; inoperable patients: pivotal trial: Leon et al¹; Continued Access: FDA.⁴

^*The weights are based on the number of participants in the pivotal and Continued Access trials.

^†Uncertainty surrounding mortality is modelled with β distributions with the same mean. The α parameter of these distributions equals the number of events in the PARTNER randomised controlled trial. For example: 5% mortality on a total of 179 patients is reflected with a β distribution with the α parameter being 9 (ie, 5% of 179=9 patients) and the β parameter being 170 (ie, 179−9).

AVR, aortic valve replacement; Cont., continued; Stand., standard therapy; TAVI, transcatheter aortic valve implantation.